Haemophilia: Current Treatment and Clinical Outcomes, Challenges and Opportunities: 2nd Edition
A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Hematology".
Deadline for manuscript submissions: closed (20 January 2026) | Viewed by 889
Special Issue Editor
Interests: hemophilia A and B; Von Willebrand disease; rare coagulation disorders; antipholipid antibodies (lupus anticoagulant, anticardiolipin antibodies); deep vein thrombosis and pulmonary embolism; venous thromboembolism; arterial thrombosis
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
We invite you to contribute to the Special Issue entitled “Haemophilia: Current Treatment and Clinical Outcomes, Challenges and Opportunities: 2nd Edition”. This is the Special Issue’s second volume; we published nine papers in the first volume. For more details, please visit https://www.mdpi.com/journal/jcm/special_issues/D7TL8NGGX0.
In recent years, several new drug treatments have been developed for treating haemophilia patients. Recombinant clotting factor concentrates FVIII/FIX extended half-life, and new haemostasis agents administered subcutaneously (weekly to monthly) are available. These innovative approaches have the potential to enhance the standard of care by decreasing infusion frequency to increase compliance, promote prophylaxis, offer alternatives to inhibitor patients, and ease the administration route.
Prophylaxis is the gold-standard treatment in haemophilia to prevent bleeding and recurrent haemarthrosis, which can progress to an haemophilic arthropathy, yet numerous issues remain with regard to new drugs. Although EHL products are promising, the optimal strategy for the treatment of bleeds between prophylactic doses and dosing regimens needs to be individualized according to patient pharmacokinetics, accounting for age and physical activity. Emicizumab appears able to improve haemostasis in haemophilia patients, probably including those with inhibitors; however, they cannot currently prevent all bleeding. This context poses the following questions: What is the best treatment for reducing the risk of severe bleeding in newborns, such as intracranial haemorrhage? Could emicizumab and EHL equally protect joints from developing haemophilic arthropathy? What is the best product for active patients? This Special Issue, entitled “Haemophilia: Current Treatment and Clinical Outcomes, Challenges and Opportunities”, will provide an overview of current and developing drugs for haemophilia treatments, providing some answers to the many questions and concerns that exist.
Prof. Dr. Ezio Zanon
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- haemophilia A and B
- FVIII EHL, FIX EHL
- prophylaxis
- emicizumab
- health-related quality of life
- population pharmacokinetics
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
